Table 1.

Growth inhibitory activity expressed as IC₅₀ (µM) of test compound SF5-SAHA and of SAHA as positive control in human prostate (DU145) and hepatoma (Hep-G2) cancer cells as well as in human T-cell leukemia/lymphoma cell lines (Jurkat, Hut78, SupT11, SMZ1), as determined after 48 h. SAHA was used as clinically relevant reference for single HDAC-inhibition. All results are described as means ± SEM of n ≥ 3 independent experiments.

Compounds	DU145	Hep-G2	Jurkat	Hut78	SupT11	SMZ1
SF5-SAHA	0.73 ± 1.08	1.79 ± 1.06	0.76 ± 0.06	2.40 ± 0.40	3.08 ± 0.33	1.58 ± 0.29
SAHA	0.68 ± 0.04	3.22 ± 0.44	1.70 ± 0.17	5.07 ± 0.42	4.67 ± 0.31	2.87 ± 0.33